

**Apobec-1 Antibodies**

Cat. # APOBEC11-P	Human Apobec-1 control peptide # 1	<b>SIZE:</b> 100 ug
Cat. # APOBEC11-A	<b>Rabbit</b> Anti-Human Apobec-1 IgG # 1 (aff pure)	<b>SIZE:</b> 100 ug

RNA editing is an important mechanism for regulating genetic plasticity through the generation of alternative protein products from a single structural gene. Substitutional RNA editing employs a variety of genetic mechanisms, the biochemical basis of which has been elucidated following the development of *in vitro* assays that recapitulate important elements of this process. There are two types of substitutional RNA exist in mammals, namely A-to-I and C-to-U RNA editing. The best-characterized example of C-to-U RNA editing involves the nuclear transcript encoding intestinal apolipoprotein B (apo B). Apo B RNA editing changes a CAA to a UAA stop codon, generating a truncated protein, apoB48. The functional complex includes a minimal core composed of apobec-1 and ACF, that function as an adaptor protein by binding both the deaminase and the RNA substrate. The RNA binding proteins also include CUGBP2 which along with Apobec-1 binds to the consensus binding sequence UUUN (A/U) U, present in c-myc, VEGF and Cyclooxygenase-2 (COX2).

**Apobec-1**, a 236aa protein in human (chr 12p13.1) an RNA specific cytidine deaminase, is essential but not efficient for apo B editing activity, there being a requirement for other protein factor. Apobec-1 is a dimer with the composite active site assembled through interaction of each monomer; In addition it is an RNA-binding protein that binds to the consensus sequence UUUN (A/U) U located within the terminal loop of apo B RNA. But finally it forms the minimal component of the core-editing enzyme along with ACF.

SUBUNIT: Homodimer. Part of the apolipoprotein B mRNA editing complex with APC. Found in a complex with CUGBP2 and ACF. APC binds to APOB mRNA and is probably responsible for docking APOBEC1 to the mRNA. Interacts with HNRPA2B1 and SYNCRIP. TISSUE SPECIFICITY: Expressed exclusively in the small intestine. SIMILARITY: Belongs to the cytidine and deoxycytidylate deaminase family.

**Source of Antigen and Antibodies**

<b>Antigen</b>	16-aa peptide from Human <b>Apobec-1</b> (gene accession # P41238, refs 1); <b>Designation (APOBEC11-P, control peptide)</b> conjugated to KLH
<b>Location</b>	~C-terminus
<b>Ab Host/type</b>	Rabbit, Polyclonal Aff pure IgG (cat # <b>APOBEC11-A</b> )
<b>2-ab</b>	<b>Goat Anti-rabbit IgG-HRP</b> cat # 20320 (AP, biotin, FITC conjugates also available)
<b>-ve control IgG</b>	<b># 20009-1, Rabbit (non-immune) IgG, purified, suitable for ELISA, Western, IHC as -ve control</b>

**Form & Storage of Antibodies/Peptide Control**

**Affinity pure IgG**  
100 ug/100ul solution lyophilized powder  
Supplied in Buffer: PBS+0.1% BSA  
**Reconstitute powder** in PBS at 1mg/ml

**Control/blocking peptide**

100 ug/100 ul solution lyophilized powder  
Supplied in Buffer: PBS pH 7.5,

**Reconstitute powder in PBS at 1 mg/ml.**

**Storage**

**Short-term:** unopened, undiluted liquid vials at -20OC and powder at 4oC or -20oC..

**Long-term:** at -20C or below in suitable aliquots after reconstitution. Do not freeze and thaw and store working, diluted solutions.

**Stability:** 6-12 months at -20oC or below.

**Shipping:** 4oC for solutions and room temp for powder.

**Recommended Usage**

**Western Blotting** (1-10 ug/ml for affinity pure antibody using ECL technique).

**ELISA:** Control peptide can be used to coat ELISA plates at 1 ug/ml and detected with antibodies (0.5-1 ug/ml for affinity pure).

**Histochemistry & Immunofluorescence:** Not tested. We recommend the use of aff pure IgG at 2-20 ug/ml.

**Specificity & Cross-reactivity**

Human APOBEC11-P control peptide is 100% conserved in chimp, 93% in pongo pygmaeus, and 75% in rabbit. The epitope is only partly (~50%) contained in mouse and rat APOBEC1. APOBEC-1. Antibody cross-reactivity in various species has not been studied. Control peptide, because of its low mol. Wt (<3 kDa), is not suitable for Western. It should be used for ELISA or antibody blocking experiments (use 5-10 ug control peptide per 1 ug of aff pure IgG or 1 ul antiserum) to confirm antibody specificity (see detailed protocol at: [www.4adi.com\data\abblock.html](http://www.4adi.com\data\abblock.html)).

**General References:** Shrikant Anant et al (2001) JBC, Vol. 276, No: 50, 47338-47351; Duanxiang Li et al (2001) Genomics 74, 396-401; Ba-Bie Teng et al (1999) J. of Lipid Research, Vol. 40, 623-633; Lu X et al (1999) Hum. Mol. Genet. 8 (1), 53-60; Fujino, T. et al (1998) Genomics 47 (2), 266-275.

\*This product is for In vitro research use only.

**Related material available from ADI**

Antibodies for CUGBP2, Apobec-1, ACF, VEGF, COX1, COX2, COX3 etc..

Apobec11-A-P 70807A

**India Contact:**

**Life Technologies (India) Pvt. Ltd.**

306, Aggarwal City Mall, Opposite M2K Pitampura, Delhi – 110034 (INDIA). Ph: +91-11-42208000, 42208111, 42208222, Mobile: +91-9810521400, Fax: +91-11-42208444  
Email: [customerservice@lifetechindia.com](mailto:customerservice@lifetechindia.com) Website: [www.lifetechindia.com](http://www.lifetechindia.com)